Free Trial
OTCMKTS:VYNT

Vyant Bio (VYNT) Stock Price, News & Analysis

Vyant Bio logo
$0.19 +0.01 (+7.78%)
(As of 12/29/2023)

About Vyant Bio Stock (OTCMKTS:VYNT)

Key Stats

Today's Range
$0.18
$0.20
50-Day Range
$0.19
$0.19
52-Week Range
$0.14
$1.58
Volume
19,100 shs
Average Volume
161,822 shs
Market Capitalization
$1.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Stock News Headlines

Vyant Bio Inc VYNT
Man Who Called Nvidia Says: “Your Retirement Is Inside This Building.”
In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company... And the stock is up massively since Jeff's recommendation.
Vyant Bio Provides Update on Winddown Activities
See More Headlines

VYNT Stock Analysis - Frequently Asked Questions

Vyant Bio's stock was trading at $0.1940 on January 1st, 2024. Since then, VYNT shares have increased by 0.0% and is now trading at $0.1940.
View the best growth stocks for 2024 here
.

Vyant Bio, Inc. (OTCMKTS:VYNT) issued its earnings results on Thursday, November, 11th. The company reported ($0.75) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.75). The company earned $1.51 million during the quarter, compared to the consensus estimate of $2.19 million. Vyant Bio had a negative net margin of 3,474.81% and a negative trailing twelve-month return on equity of 151.82%.

Vyant Bio shares reverse split on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vyant Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/11/2021
Today
12/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
OTCMKTS:VYNT
Employees
30
Year Founded
N/A

Profitability

Net Income
$-22,690,000.00
Net Margins
-3,474.81%
Pretax Margin
-3,281.86%

Debt

Sales & Book Value

Annual Sales
$670,000.00
Book Value
$1.69 per share

Miscellaneous

Free Float
5,724,000
Market Cap
$1.23 million
Optionable
Not Optionable
Beta
1.73
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (OTCMKTS:VYNT) was last updated on 12/26/2024 by MarketBeat.com Staff
From Our Partners